Arvinas to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will present at two virtual investor conferences. The first is the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, featuring a pre-recorded chat with management. The second conference is the 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 3, 2020, with live participation from key executives. Arvinas is dedicated to developing therapies for debilitating diseases using its proprietary PROTAC® platform, targeting proteins causing various conditions.

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences:

Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020. A pre-recorded fireside chat held with John Houston, Ph.D., President and Chief Executive Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, is available here and on the Events + Presentations section of the Company’s website.

3rd Annual Evercore ISI HealthCONx Virtual Conference on Thursday, December 3, 2020. Ian Taylor, Ph.D., Chief Scientific Officer, and Randy Teel, Ph.D., Vice President of Corporate Development, will participate in a fireside chat at 8:50 a.m. ET. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com

FAQ

What is the date of Arvinas' participation in the Piper Sandler Virtual Healthcare Conference?

Arvinas will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020.

Who will represent Arvinas at the Evercore ISI HealthCONx Virtual Conference?

Ian Taylor and Randy Teel will represent Arvinas at the Evercore ISI HealthCONx Virtual Conference on December 3, 2020.

What technology does Arvinas use to develop its therapies?

Arvinas uses its proprietary PROTAC® Discovery Engine platform, which focuses on targeted protein degradation.

What therapies is Arvinas currently developing?

Arvinas is developing ARV-110 for metastatic castrate-resistant prostate cancer and ARV-471 for ER+/HER2- breast cancer.

Where can I find more information about Arvinas?

More information about Arvinas can be found on their official website at www.arvinas.com.